Systematic evaluation of absent pubertal signs at age 13 (girls) / 14 (boys) — LH/FSH branches the differential into hypogonadotropic and hypergonadotropic pathways
Puberty timing varies enormously across a healthy population, so "delayed puberty" is a statistical definition: absence of the first physical sign of puberty roughly two standard deviations later than the population mean. In practice this means no breast budding (Tanner stage 2) by age 13 in girls, and testicular volume remaining under 4 mL (or longest axis <2.5 cm) by age 14 in boys. Before ordering a single lab test, a careful history and growth chart review often already points toward the most common diagnosis: constitutional delay of growth and puberty.
Puberty is driven by reactivation of the hypothalamic-pituitary-gonadal (HPG) axis after its infantile quiescence ("gonadostat" resetting). Pulsatile GnRH secretion resumes, driving pituitary LH/FSH pulses that stimulate gonadal sex-steroid production. The population distribution of pubertal onset is roughly Gaussian:
• Girls: mean thelarche onset ~10.5 years; 2 SD threshold ≈ 13 years • Boys: mean onset of testicular enlargement ~11.5 years; 2 SD threshold ≈ 14 years
A second, complementary definition uses tempo: girls who have not achieved menarche within 3 years of thelarche onset, or anyone with no progression through Tanner stages over 2 years, also warrants evaluation even if the initial sign appeared on time — pubertal arrest is as concerning as pubertal absence.
Girls are diagnosed roughly 2–3× less often than boys, partly because delayed puberty carries more social visibility for boys (height, voice, muscle mass) and partly because girls with hypergonadotropic causes (Turner syndrome) are frequently identified earlier via short stature screening.
A structured history frequently narrows the differential dramatically before any blood is drawn:
Family pubertal timing: • Age of mother's menarche, age father started shaving/had growth spurt • A parent with self-reported "late bloomer" history strongly predicts constitutional delay (CDGP), which has a clear autosomal-dominant-like familial pattern in a large minority of cases (some traced to IGSF10 or other GnRH-neuron migration genes)
Growth trajectory: • CDGP: height percentile drifts downward in mid-childhood but growth velocity itself stays normal to low-normal, and bone age is delayed proportionally to the height deficit (predicted adult height normalizes) • Organic hypopituitarism: growth velocity is frankly subnormal, unrelated to bone age delay
Chronic disease and nutritional screen: • Celiac disease, inflammatory bowel disease, cystic fibrosis, chronic kidney disease, poorly controlled diabetes, and severe asthma all suppress GnRH pulsatility via cytokine and energy-deficit signaling • Eating disorders and relative energy deficiency in sport (RED-S): ask about caloric intake, menstrual history, exercise volume, and body image directly and non-judgmentally • Anosmia or hyposmia (never noticed smelling food, perfume) is the single highest-yield question for Kallmann syndrome and should be asked of every patient regardless of sex
Medication and treatment history: • Prior chemotherapy, pelvic/cranial radiation, or glucocorticoid exposure raises suspicion for gonadotoxicity or hypothalamic-pituitary damage
A single question set — "Did either parent go through puberty late?" plus "Have you ever had trouble smelling things?" — has outsized diagnostic yield: it screens simultaneously for the most common benign cause (constitutional delay) and one of the most specific organic causes (Kallmann syndrome) before a single lab value is available.
After history, growth chart review, and a bone age radiograph, the single lab result that reorganizes the entire differential diagnosis is basal (or GnRH-stimulated) serum LH and FSH. This one test partitions delayed puberty into two mechanistically opposite categories: hypogonadotropic hypogonadism, where the hypothalamus or pituitary is under-driving otherwise capable gonads, and hypergonadotropic hypogonadism, where the pituitary is shouting at gonads that cannot respond.
Serum gonadotropins report on the status of the hypothalamic-pituitary-gonadal axis feedback loop with remarkable directness:
Low or normal (prepubertal-range) LH/FSH: • Implies the hypothalamus is not yet driving pulsatile GnRH release adequately, OR the pituitary cannot respond to GnRH • The gonads themselves are presumed intact and simply un-stimulated • This is the more common pattern and includes the single most frequent cause of delayed puberty overall — constitutional delay — as well as functional and organic hypogonadotropic hypogonadism
Elevated LH/FSH (particularly FSH, which rises earliest and most reliably in primary gonadal failure): • Implies the gonad cannot produce sex steroids or inhibin, so there is no negative feedback on the pituitary • The pituitary compensates by secreting ever-more gonadotropin — an appropriate response to gonadal failure • This pattern mandates a karyotype, because chromosomal gonadal dysgenesis (Turner, Klinefelter) is the leading cause
Ambiguous mid-range values are common in early puberty and may require a GnRH agonist stimulation test (leuprolide) to unmask the axis: an exaggerated LH rise suggests imminent spontaneous puberty (favors constitutional delay), while a blunted response favors true gonadotropin deficiency.
Gonadotropins are rarely ordered in isolation. A standard first-tier panel drawn at the same visit typically includes:
• Bone age radiograph (left hand/wrist): delayed bone age relative to chronological age supports constitutional delay or any hypogonadotropic cause; bone age close to chronological age with elevated gonadotropins is more typical of hypergonadotropic failure • Estradiol (girls) or early-morning testosterone (boys): confirms the low sex-steroid state biochemically • TSH/free T4: hypothyroidism independently delays puberty and is easily corrected • Prolactin: hyperprolactinemia suppresses GnRH pulsatility and may indicate a pituitary lesion • IGF-1/IGFBP-3: screens for growth hormone deficiency, which frequently coexists with hypogonadotropic hypogonadism in combined pituitary hormone deficiency • CBC, ESR/CRP, celiac serologies, complete metabolic panel: screen for occult chronic disease driving functional suppression
The combination of these results — not gonadotropins alone — determines whether the workup proceeds down the hypogonadotropic or hypergonadotropic branch in the next stage.
The hypogonadotropic branch is the more heavily populated fork, and the diagnostic task shifts from "is this an axis problem" to "which kind." The great majority of these patients have constitutional delay of growth and puberty (CDGP) — a normal variant, not a disease — but functional suppression from chronic illness or energy deficit, and organic hypogonadotropic hypogonadism (GnRH deficiency, Kallmann syndrome, pituitary tumor), must be actively ruled out because their management differs substantially.
CDGP is a normal variant of the tempo of maturation, not a pathological process. It accounts for roughly two-thirds of hypogonadotropic presentations and is diagnosed by a consistent constellation:
• Delayed bone age (typically 2 years or more behind chronological age) that closely matches height age — predicted adult height, once corrected for bone age, falls within the genetic target range • Positive family history of delayed puberty in a parent or sibling • Normal growth velocity for bone age (not for chronological age) • Normal, low-normal, or pubertal-range (but not yet clinically apparent) gonadotropins that rise appropriately on GnRH stimulation testing • Absence of red-flag findings: normal sense of smell, no midline defects, no chronic disease markers, no galactorrhea or visual field deficit
CDGP is fundamentally a diagnosis of exclusion supported by these positive features — it is confirmed retrospectively when puberty eventually begins spontaneously, almost always by age 18.
Any state of chronic energy deficit, inflammation, or severe psychological stress can suppress hypothalamic GnRH pulse generation as an adaptive, reversible mechanism — the body deprioritizes reproduction when survival resources are limited:
• Chronic disease: inflammatory bowel disease, celiac disease, cystic fibrosis, chronic kidney disease, poorly controlled type 1 diabetes • Energy deficit: anorexia nervosa, avoidant/restrictive food intake disorder, relative energy deficiency in sport (RED-S) from high training volume with inadequate caloric intake • Severe psychosocial stress or major depressive illness
The biochemical signature overlaps heavily with CDGP (low/normal gonadotropins, delayed bone age), so the history and targeted labs (ESR/CRP, celiac serology, weight-for-height trajectory, menstrual/exercise history) are what separate this category — treatment of the underlying illness or nutritional rehabilitation typically restores pubertal progression.
Organic HH results from a structural or genetic defect in GnRH neuron development, migration, or secretion, or from a mass lesion disrupting the hypothalamic-pituitary unit:
• Congenital GnRH deficiency (isolated hypogonadotropic hypogonadism, IHH): failure of normal GnRH pulsatility from birth, due to mutations in genes such as GNRHR, KISS1R/KISS1, TAC3/TACR3, or FGFR1 • Kallmann syndrome: IHH plus anosmia/hyposmia, caused by failure of GnRH neurons to co-migrate with olfactory axons from the nasal placode during embryogenesis (KAL1/ANOS1, FGFR1, PROK2/PROKR2 and others); may also feature synkinesia, renal agenesis, or cleft lip/palate • Pituitary or hypothalamic tumor: craniopharyngioma, germinoma, or prolactinoma can compress the pituitary stalk or gonadotrope population — look for headache, visual field cut, growth deceleration, diabetes insipidus, or other pituitary hormone deficiencies • Prior cranial irradiation or traumatic brain injury
Red flags that mandate pituitary/hypothalamic MRI: anosmia, other midline craniofacial defects, neurologic or visual symptoms, growth hormone deficiency or other pituitary hormone deficits, discordantly severe or complete gonadotropin deficiency, or any history of cranial radiation.
Anosmia is the clinical hinge of this branch: a patient with low gonadotropins, normal smell, delayed bone age, and a family history of late puberty is treated as constitutional delay and observed. The same lab picture with an inability to smell coffee or perfume becomes Kallmann syndrome until proven otherwise, and triggers pituitary MRI and genetic counseling rather than watchful waiting.
When LH and especially FSH return elevated, the diagnostic question is no longer whether the axis is intact — it clearly is, and is working overtime — but why the gonad itself cannot respond. Primary gonadal failure has a short, high-yield differential dominated by chromosomal gonadal dysgenesis, making karyotype the single most important next test in this branch.
Turner syndrome (45,X or mosaic variants such as 45,X/46,XX) is the leading cause of hypergonadotropic hypogonadism in girls, driven by accelerated ovarian follicle atresia — "streak gonads" that fail well before or during the expected age of puberty:
• Clinical clues predating the pubertal evaluation: short stature (frequently the presenting complaint years earlier), webbed neck, low posterior hairline, broad shield chest, cubitus valgus, lymphedema of hands/feet in infancy • Associated findings to screen for once suspected: bicuspid aortic valve/coarctation of the aorta (echocardiogram), horseshoe kidney (renal ultrasound), hearing loss, autoimmune thyroiditis, celiac disease, and osteoporosis risk • Mosaic forms may have milder or absent phenotypic stigmata and can occasionally have some spontaneous pubertal development before ovarian failure accelerates — do not let a normal appearance exclude the diagnosis • Diagnosis is confirmed by peripheral blood karyotype (often 30-cell count to detect low-level mosaicism)
Klinefelter syndrome (47,XXY, or higher-grade variants/mosaics) is the leading chromosomal cause of hypergonadotropic hypogonadism in boys, from progressive seminiferous tubule hyalinization and Leydig cell dysfunction:
• Often under-recognized before puberty: tall stature with disproportionately long legs, mild learning or language delay, small firm testes that are the key discriminating exam finding — testes may be present but disproportionately small for the degree of virilization • At puberty: incomplete virilization, gynecomastia, small testicular volume with rising gonadotropins as Sertoli/Leydig function declines • Long-term associations: infertility (azoospermia in the large majority), increased risk of metabolic syndrome, and modestly increased breast cancer risk relative to XY males • Diagnosis confirmed by karyotype; testicular sperm extraction with assisted reproduction is possible in a subset if fertility is desired
When karyotype is normal (46,XX or 46,XY), the hypergonadotropic differential broadens to acquired causes of gonadal failure:
• Autoimmune oophoritis/orchitis: often part of autoimmune polyglandular syndrome; screen with adrenal (21-hydroxylase) and thyroid antibodies, and consider associated autoimmune adrenal insufficiency • Gonadotoxic chemotherapy or radiation: alkylating agents (cyclophosphamide) and pelvic/testicular or craniospinal radiation are directly toxic to germ cells and, at higher doses, to Leydig/theca cells — always ask specifically about prior oncologic treatment, since it is easy to omit from a routine history • Galactosemia, viral orchitis (mumps), testicular torsion or trauma, or vanishing testes syndrome in boys • Rare single-gene disorders of gonadal development (e.g., FSH/LH receptor mutations, steroidogenic enzyme defects) when the phenotype and family history suggest a Mendelian pattern
Regardless of cause, once primary gonadal failure is confirmed, the long-term management is similar: sex-steroid replacement to induce and maintain secondary sexual characteristics, bone health, and psychosocial well-being, with fertility counseling addressed early since natural fertility is usually significantly impaired.
Any hypergonadotropic hypogonadism in a child with a history of childhood cancer treatment should prompt a targeted review of chemotherapy agents and cumulative radiation dose rather than an automatic karyotype-first approach — the pattern of gonadal injury (and the counseling about fertility preservation options that should have preceded treatment) differs from congenital gonadal dysgenesis.
Once the branch point (hypogonadotropic vs hypergonadotropic) and the specific diagnosis within it are established, management diverges sharply. Constitutional delay needs reassurance and time; hypogonadotropic hypogonadism needs the axis restarted, either physiologically for fertility or simply with sex steroids; hypergonadotropic hypogonadism needs lifelong sex-steroid replacement and early fertility counseling because the gonad itself will not recover.
Because CDGP is a normal variant, the mainstay of management is education and reassurance for the patient and family, with close monitoring of growth and pubertal progression every 3–6 months to confirm the expected spontaneous onset. For patients experiencing significant psychosocial distress, bullying, or anxiety about being visibly behind peers, a short priming course of sex steroid can be offered:
• Boys: low-dose intramuscular testosterone (e.g., 50–100 mg monthly) for 3–6 months to induce early virilization and a growth spurt without materially advancing bone age or compromising adult height, followed by a treatment pause to confirm the endogenous axis has engaged • Girls: low-dose oral or transdermal estrogen for a similarly brief, carefully monitored course
This is a bridge, not a permanent replacement — therapy is stopped after a short course specifically to observe whether the patient's own axis takes over, which is the expected outcome in true CDGP.
Management depends on whether the immediate goal is inducing secondary sexual characteristics or achieving fertility:
Sex-steroid replacement (fertility not an immediate priority): • Testosterone (boys) or estrogen, later with cyclic progesterone (girls), titrated slowly upward over 2–3 years to mimic the natural tempo of puberty, avoiding premature bone age advancement and compromised final height
Fertility induction (when pregnancy or spermatogenesis is desired, typically in adulthood): • Pulsatile GnRH via subcutaneous pump, mimicking physiologic hypothalamic secretion — most physiologic option when the pituitary gonadotrope is intact (i.e., a hypothalamic rather than pituitary defect) • Exogenous gonadotropin therapy (hCG for LH activity plus recombinant FSH) when pulsatile GnRH is unavailable or the defect is pituitary-level — directly stimulates Leydig/testicular or ovarian/follicular function
Functional hypogonadotropic hypogonadism from chronic illness, eating disorder, or over-exercise is managed by treating the underlying driver (nutritional rehabilitation, disease control, training-load adjustment) rather than by sex-steroid replacement alone, since the axis typically recovers once the precipitant resolves.
Because the gonad itself has failed, sex-steroid replacement is typically lifelong, and the counseling conversation about fertility should begin as early as developmentally appropriate:
• Girls (e.g., Turner syndrome): ultra-low-dose transdermal 17β-estradiol started around age 11–12 and slowly up-titrated over 2–3 years to induce breast development at a physiologic tempo, with cyclic progestin added once breakthrough bleeding occurs or after 2 years of estrogen; lifelong estrogen replacement (until natural menopause age) supports bone density and cardiovascular health; fertility usually requires donor oocyte IVF, though fertility preservation counseling and, in select mosaic cases, oocyte cryopreservation may be discussed • Boys (e.g., Klinefelter syndrome): testosterone replacement once puberty should be progressing, titrated to adult physiologic levels over time; fertility is possible for a subset via testicular sperm extraction (TESE) combined with assisted reproduction, best pursued as early as feasible given progressive testicular fibrosis • All patients: baseline and periodic bone mineral density assessment given the elevated osteoporosis risk of prolonged sex-steroid deficiency, plus condition-specific surveillance (e.g., cardiac/renal imaging and autoimmune screening in Turner syndrome; metabolic and breast health monitoring in Klinefelter syndrome)
The management pathway is not just diagnosis-specific but time-sensitive: fertility preservation counseling and options are far broader when raised proactively at diagnosis than when revisited years later after further gonadal decline — this conversation belongs at the first management visit, not deferred until adulthood.